From: Vita-More, Natasha (NatashaVi@chadbourne.com)
Date: Tue Mar 14 2000 - 10:32:56 MST
"Germany Sees Biotech Field With New Eyes"
Science: A convergence of events frees researchers and creates an exciting
new industry devoted to medical advances. By Carol J. Williams, LA Times
Staff Writer, 3/14/00
MARTINSRIED, Germany--When noted biochemistry professor Ernst-Ludwig
Winnacker began lobbying the government for a gene research center in the
mid-1980s, the very notion of trying to crack the human genetic code was so
taboo that he became a target of radical environmentalists and the terrorist
Red Army Faction.
So unwelcome was any thought of "interfering with God" in rewriting the
human body's computer program, Winnacker recalls, that the government had to
post armed guards outside his home and sheathe his office in bulletproof
glass.
But as the best and brightest of German scientists fled to the more
supportive environment of U.S. labs and contributed to breakthroughs in
treating debilitating and fatal diseases, Germans came to the conclusion
that gene technology offered great promise in improving the quality and
longevity of life.
And suddenly, as one recently repatriated entrepreneur puts it,
"biotech start-ups began sprouting up around here like mushrooms after a
warm rain." More than 600 German firms are now engaged in genetic research,
the vast majority founded within the last five years.
This glass-and-steel industrial park on the outskirts of Munich has
become an incubator for biotech business in that short time span. Many of
the small private firms rising from the ubiquitous construction sites are
flush with newfound venture capital and income from initial public offerings
of stock.
It's been made possible by a synergy of reversed public sympathies,
watershed genetic discoveries and a changing attitude in this country toward
entrepreneurial success and personal wealth.
The convergence of events has given Germany and its scientific elite a
chance to do their part in treating what ails the world, from AIDS to
cancer.
And, say industry leaders, the biotech boom has created the opportunity
for Germany's once-vaunted pharmaceutical giants such as Bayer, Hoechst and
Schering to recover their global positions after 15 years of
"biotechnophobia" that allowed U.S. competitors to surge to the fore.
Although the biotechnology discoveries of the 1970s and '80s benefited
the U.S. labs that underwrote them, many German scientists were instrumental
in the developments. Some have returned to their homeland now that the
atmosphere is more supportive.
Axel Ullrich, who cloned the first gene for human insulin during his
postdoctoral work at UC San Francisco and helped develop a drug for
treatment of breast cancer while at Sugen Inc. in Redwood City, Calif., now
divides his time between business interests in the United States and this
biotech village.
Like others watching the rapid expansion of gene and genome technology
here, he senses a sea change in attitudes among German scientists and within
the ossified halls of academia that have long suppressed entrepreneurial
spirits.
"These uncomplicated, aggressive, let's-just-do-it kind of guys you
find in the United States--we just didn't have that here," Ullrich said.
"But I've been pleasantly surprised to see young people now adopting those
styles and attitudes. There's such enthusiasm now, which is another German
syndrome. We have a tendency to sleep for a long time, then dive into
something with tremendous zeal and pursuit of perfection."
Among the attitudinal changes he sees from a decade ago is the
increasing acceptance, even admiration, of those who become rich from their
inventions.
"When I came back 10 years ago, it was assumed by everyone that I had
made a pile of money, and I felt very excluded," Ullrich says of the
professional cold shoulder then given those who made their mark in U.S.
laboratories, where top scientists are better compensated than at German
facilities. "This reaction of envy is still a problem, but it's much better
now."
He and other leading genetic researchers spent the early years of their
careers across the Atlantic because there was virtually no opportunity to do
the work in Germany in the face of such strident public protest, he says.
Even the big pharmaceutical companies that wanted to invest in gene research
sent their money overseas to avoid becoming political targets.
Hoechst, once the world's No. 1 drug manufacturer, poured $200 million
into a gene lab at Massachusetts General Hospital in the 1980s. Other big
players in Germany had decided that they didn't need to back biotechnology
at all because they could buy it from the U.S. leaders, said Ullrich.
But much of that has changed. "There is far more insight now into the
benefits of biotechnology, especially in the life science fields. There are
new vaccines and new drugs now capable of treating the causes of disease,
not just symptoms," said Bernhard Hertel, managing director of Garching
Innovation, a Max Planck Society offspring that helps create viable private
companies from the state-financed research network.
Over the last decade, Garching has played midwife to 31 start-ups that
have created more than 1,000 jobs and has 13 projects in the works this
year, said Hertel. The first private company spun off was Sugen, recently
bought by Pharmacia & Upjohn Inc., the U.S. pharmaceutical giant.
Winnacker, who no longer needs police protection, is now on leave from
his professorship at the University of Munich to oversee the German Research
Society, a Bonn-based federal agency that functions like a hybrid of the
National Institutes for Health and the National Science Foundation in the
United States.
"Gene research was an important stage, but genomics is a revolution," the
mild-mannered academic says about the relatively new science exploring the
interaction of the genetic code. "This makes it possible to analyze the
complex biological aspects of diseases like cancer so we know why it
develops the way it does and how we might influence it. The outlook is
incredible."
Among the projects in the works here is an examination of how nerve cells
are genetically programmed to prevent their reproducing themselves after
being severed--information that could one day make it possible to reverse
paraplegia, Winnacker said. Others involve development of drugs to treat
Alzheimer's, Parkinson's and other degenerative diseases.
"We lost a considerable amount of time, but genomics discoveries came
so much later that they have leveled the playing field somewhat," Winnacker
said. "Now, the situation is very good for German scientists to remain here.
The question is how to get more American scientists to come here, to mix it
up a bit."
Germany's turnabout on gene research was spurred by an ambitious
government project in the mid-1990s that made matching funds available for
biotech start-ups in three designated regions in and around the cities of
Cologne, Heidelberg and Munich.
"Germany was one of the major high-technology countries in the world
after the United States and Japan, and some people suddenly realized
biotechnology is the way of the future," said Bernd Seizinger, who left his
home and business in Princeton, N.J., last year to head Genome
Pharmaceuticals Co. here. "There needs to be enormous effort made not only
to get into this field but to catch up to the United States."
He described the availability of venture capital here as better than
across the Atlantic at the moment and thoroughly revolutionized from a
decade ago, when hardly a German citizen risked investing his savings in
anything but a low-return passbook account.
Like other movers in the science community, Seizinger sees the fever of
mergers and acquisitions among the pharmaceutical titans as an opportunity
for biotech firms to take on responsibility for important medicinal
breakthroughs. Firms like his make the discoveries, then the big drug
companies use their production, marketing and distribution power to bring
the products to the consumer.
"Most pharmaceutical companies are driven by the products they sell,
not [research and development]," he said. "A biotech company's value is in
the creativity of its people."
Exuding the enthusiasm of an inventor, he described how genome research
is mapping the "computer program that tells the body how to live" and will
one day allow medicine to intervene when the program is defective.
"We're just at the beginning of this," he insists. "It's . . . a true
paradigm shift in the history of medicine. He describes the pace of genome
discoveries as so accelerated that Germany may catch up to U.S. counterparts
despite its 15-to-20-year lag in getting started.
German firms still play a minor role in comparison with U.S. companies,
which account for more than 330 of the 400 publicly traded biotechnology
companies listed on the world's stock markets, German media report. But two
of the most recent IPOs, Hamburg's Evotech and local start-up MorphoSys,
have seen their stock values more than quintuple since launching in October.
Opposition remains fierce in Europe to what scientists call "green
genetics," or modification of the basic substances of crops and animals. But
scientists say this resistance will dissipate as well once the global public
is educated about the value it offers in feeding the world's growing ranks
of hungry citizens.
"This technology will change our lives, especially if we overcome our
food phobia," says Ullrich, trumpeting genetic engineering's promise for
feeding the Third World and shielding food from disease, toxins and the
whims of weather. "As long as Earth wants to sustain an ever-increasing
population, it must expand these branches of science. People want to live
longer, healthier lives."
***************************************************************************
This e-mail, and any attachments thereto, is intended only for use by the
addressee(s) named herein and may contain legally privileged and/or
confidential information. If you are not the intended recipient of this
e-mail, you are hereby notified that any dissemination, distribution or
copying of this e-mail, and any attachments thereto, is strictly prohibited.
If you have received this e-mail in error, please notify me by replying to
this message and permanently delete the original and any copy of this
e-mail and any printout thereof.
This archive was generated by hypermail 2.1.5 : Fri Nov 01 2002 - 15:27:23 MST